Infections from respiratory syncytial virus (RSV) in children requiring primary care led to significant societal economic costs from outpatient treatment and parental work absences in Europe, ...

Infections from respiratory syncytial virus (RSV) in children requiring primary care led to significant societal economic ...

The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines for ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

Widespread use of maternal RSV vaccination and nirsevimab during the 2024–2025 U.S. RSV season led to a significant reduction ...

As winter nears and the cold and flu season sets in, the highly infectious respiratory virus RSV has again begun its ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Couldn't resolve component "default" at "/:pathMatch (.*)?/:lcsId ( [0-9]\- [0-9]\- [0-9]+| [0-9]- [0-9]- [0-9]+PT [0-9]+)" ...

Nirsevimab is effective for reducing the burden of respiratory syncytial virus (RSV) in infants in real-world settings.

Former White House executive chef Cristeta Comerford says it was a “big eye-opener” to see that presidents and their families ...

Recent findings of the impact of new RSV prevention products aimed at protecting babies were published in the Morbidity and Mortality Weekly Report, an epidemiological digest prepared by the Centers ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.